December 2024 FDA updates: Approved treatments include
ustekinumab-kfce
○
Search Drug
for inflammatory diseases,
crinecerfont
○
Search Drug
for CAH,
nemolizumab
○
Search Drug
for AD, and
olezarsen
○
Search Drug
for FCS. Notable actions: RMAT designation for
rexlemestrocel-L
○
Search Drug
, Boxed Warning for
fezolinetant
○
Search Drug
, and CRLs for
glepaglutide
○
Search Drug
and
sotagliflozin
○
Search Drug
. Pipeline updates:
Tirzepatide
○
Search Drug
outperformed semaglutide in weight loss, and novel therapies for HCV, PNH, and EoE showed promise.